Abuse liability of quetiapine (Xeroquel?)

Objective. - In recent years, there have been several reports in the literature concerning the misuse and abuse of quetiapine. The aim of this study was to review the data reported to the French network of the addictovigilance centers as welt as the published data. Methods. - Epidemiological data from the studies of French network addictovigilance centers (spontaneous notifications, suspicious prescriptions suggesting possible abuse [ordonnances suspectes indicateur d'abus possibles. OSIAP], observatory of illegal psychotropic substances or delivered substances diverted from their medicinal use survey [observation des produits psychotropes illicites ou detournes de teur utilisation medicamenteuse, OPPIDUM], deaths related to medication and substance abuse survey [deces en relation avec l'abus de medicaments et de substances, DRAMES]) were analyzed between 2011 and 2014. All cases of abuse and dependence with quetiapine in PubMed were reviewed using the MeSH terms "quetiapine", "substances abuse", and "dependence", until October 2014. Results. - The analysis of the literature has identified 21 cases of abuse related to quetiapine, mainly in men (85.7 %), with a history of substance abuse (70%). The main route of administration was oral but other routes were also reported (intravenous, intranasal). The main reason for abuse was sedation and anxiolytic. Other characteristics of quetiapine abuse include amplification or even simulation of psychotic symptoms to obtain quetiapine, an increased dose and the existence of street names. The French addictovigilance network reported few cases of abuse with quetiapine. Discussion/Conclusion. - The pharmacological mechanism of abuse of quetiapine is not fully understood. However, several arguments are in favor of the abuse liability of quetiapine. Despite the recent availability of quetiapine in France, there have been some isolated signals of abuse. Therefore, it seems important to inform prescribers on the risk of misuse of quetiapine and also of some other antipsychotics. (C) 2016 Societe francaise de pharmacologie et de therapeutique. Published by Elsevier Masson SAS. All rights reserved.